Liver transplantation in treatment of cirrhotic portal hypertension

doi:10.16139/j.1007-9610.2021.03.002

Abstract

CLC Number:

R657.34

LI Tao, CHEN Hao. Liver transplantation in treatment of cirrhotic portal hypertension[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 189-194.

Figures/Tables 1

References 32

[33]	Ng CK, Chan MH, Tai MH, et al. Hepatorenal syndrome[J]. Clin Biochem Rev, 2007, 28(1):11-17.
[34]	Terra C, Mattos ÂZ, Pereira G, et al. Recommendations of the Brazilian Society of Hepatology for the management of acute kidney injury in patients with cirrhosis[J]. Arq Gastroenterol, 2018, 55(3):314-320. doi: 10.1590/s0004-2803.201800000-71 URL
[35]	Mindikoglu AL, Pappas SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(2):162-177. doi: 10.1016/j.cgh.2017.05.041 URL
[36]	Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation[J]. Hepatology, 2005, 41(6):1282-1289. pmid: 15834937
[37]	Utako P, Emyoo T, Anothaisintawee T, et al. Clinical outcomes after liver transplantation for hepatorenal syndrome: a systematic review and meta-analysis[J]. Biomed Res Int, 2018, 2018:5362810.
[38]	Wong F, Leung W, Al Beshir M, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation[J]. Liver Transpl, 2015, 21(3):300-307. doi: 10.1002/lt.24049 URL
[39]	Francoz C, Durand F, Kahn JA, et al. Hepatorenal syndrome[J]. Clin J Am Soc Nephrol, 2019, 14(5):774-781. doi: 10.2215/CJN.12451018 URL
[40]	Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020, 16(3):137-155. doi: 10.1038/s41581-019-0218-4 URL
[41]	Razavi-Khorasani N, Moazzami B, Dooghaie Moghadam A, et al. Pulmonary complications in candidates for liver transplantation[J]. Middle East J Dig Dis, 2020, 12(3):145-153. doi: 10.34172/mejdd.2020.176 URL
[42]	Goldberg DS, Krok K, Batra S, et al. Impact of the he-patopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database[J]. Gastroenterology, 2014, 146(5):1256-1265. doi: 10.1053/j.gastro.2014.01.005 pmid: 24412528
[43]	Cywinski JB, Makarova N, Arney A, et al. Resources utilization after liver transplantation in patients with and without hepatopulmonary syndrome: Cleveland Clinic experience[J]. Transplant Direct, 2020, 6(4):e545. doi: 10.1097/TXD.0000000000000990 URL
[44]	Schenk P, Schöniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis[J]. Gastroenterology, 2003, 125(4):1042-1052. pmid: 14517788
[45]	Gupta S, Krowka MJ. Hepatopulmonary syndrome[J]. CMAJ, 2018, 190(8):E223. doi: 10.1503/cmaj.170253 URL
[46]	Iyer VN, Swanson KL, Cartin-Ceba R, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era[J]. Hepatology, 2013, 57(6):2427-2435. doi: 10.1002/hep.26070 URL
[47]	Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm[J]. Hepatology, 2006, 44(6):1502-1510. doi: 10.1002/hep.21431 URL
[48]	Cartin-Ceba R, Krowka MJ. Pulmonary complications of portal hypertension[J]. Clin Liver Dis, 2019, 23(4):683-711. doi: S1089-3261(19)30042-X pmid: 31563218
[49]	Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups[J]. Am J Transplant, 2008, 8(11):2445-2453. doi: 10.1111/j.1600-6143.2008.02384.x pmid: 18782292
[50]	Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation[J]. Liver Transpl, 2000, 6(4):443-450. doi: 10.1053/jlts.2000.6356 URL
[51]	Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation, 2016, 100(7):1440-1452. doi: 10.1097/TP.0000000000001229 URL
[52]	Raevens S, Colle I, Reyntjens K, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values[J]. Liver Transpl, 2013, 19(6):602-610. doi: 10.1002/lt.23649 URL
[53]	Lasch HM, Fried MW, Zacks SL, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome[J]. Liver Transpl, 2001, 7(2):147-149. doi: 10.1053/jlts.2001.21287 URL
[54]	Huang L, Yu QS, Zhang Q, et al. Transjugular intrahe-patic portosystemic shunt versus surgical shunting in the management of portal hypertension[J]. Chin Med J (Engl), 2015, 128(6):826-834.
[55]	Henderson JM. Surgical treatment of portal hypertension[J]. Baillieres Best Pract Res Clin Gastroenterol, 2000, 14(6):911-925. pmid: 11139346
[56]	Chen H, Turon F, Hernández-Gea V, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation[J]. Liver Transpl, 2016, 22(3):352-365. doi: 10.1002/lt.24387 URL
[57]	Violi F, Corazza GR, Caldwell SH, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry[J]. Intern Emerg Med, 2016, 11(8):1059-1066. doi: 10.1007/s11739-016-1416-8 URL
[58]	Stine JG, Shah PM, Cornella SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis[J]. World J Hepatol, 2015, 7(27):2774-2780. doi: 10.4254/wjh.v7.i27.2774 URL
[59]	D'amico G, de Franchis R. Upper digestive bleeding in cirrhosis. post-therapeutic outcome and prognostic indicators[J]. Hepatology, 2003, 38(3):599-612.
[60]	Rugivarodom M, Charatcharoenwitthaya P. Nontumoral portal vein thrombosis: a challenging consequence of li-ver cirrhosis[J]. J Clin Transl Hepatol, 2020, 8(4):432-444. doi: 10.14218/JCTH.2020.00067 pmid: 33447527
[61]	Zanetto A, Rodriguez-Kastro KI, Germani G, et al. Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis[J]. Transpl Int, 2018, 31(12):1318-1329. doi: 10.1111/tri.13353 URL
[62]	Vianna RM, Mangus RS, Kubal C, et al. Multivisceral transplantation for diffuse portomesenteric thrombosis[J]. Ann Surg, 2012, 255(6):1144-1150. doi: 10.1097/SLA.0b013e31825429c0 URL
[1]	de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis[J]. Clin Liver Dis, 2001, 5(3):645-663. pmid: 11565135
[2]	Hackl C, Schlitt HJ, Renner P, et al. Liver surgery in cirrhosis and portal hypertension[J]. World J Gastroenterol, 2016, 22(9):2725-2735. doi: 10.3748/wjg.v22.i9.2725 URL
[3]	Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models[J]. Hepatol Int, 2018, 12(Suppl 1):1-10.
[4]	Garcia-Tsao G. The use of nonselective beta blockers for treatment of portal hypertension[J]. Gastroenterol Hepatol, 2017, 13(10):617-619.
[5]	Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 annual data report: liver[J]. Am J Transplant, 2017, 17(Suppl 1):174-251. doi: 10.1111/ajt.14126 URL
[6]	Iwatsuki S, Starzl TE, Todo S, et al. Liver transplantation in the treatment of bleeding esophageal varices[J]. Surgery, 1988, 104(4):697-705.
[7]	Wood RP, Shaw BW Jr, Rikkers LF. Liver transplantation for variceal hemorrhage[J]. Surg Clin North Am, 1990, 70(2):449-461. doi: 10.1016/S0039-6109(16)45091-7 URL
[8]	Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124(1):91-96. doi: 10.1053/gast.2003.50016 URL
[9]	Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant wai-ting list[J]. N Engl J Med, 2008, 359(10):1018-1026. doi: 10.1056/NEJMoa0801209 URL
[10]	Mahmud N. Selection for liver transplantation: indications and evaluation[J]. Curr Hepatol Rep, 2020:1-10.
[11]	Martin P, Dimartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Hepatology, 2014, 59(3):1144-1165. pmid: 24716201
[12]	Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis[J]. Liver Int, 2012, 32(9):1407-1414. doi: 10.1111/j.1478-3231.2012.02830.x URL
[13]	D'amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995, 22(1):332-354.
[14]	Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J]. Am J Gastroenterol, 2007, 102(9):2086-2102. pmid: 17727436
[15]	Zocco MA, di Stasio E, de Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol, 2009, 51(4):682-689. doi: 10.1016/j.jhep.2009.03.013 URL
[16]	徐骁, 郭海军, 李望遥. 肝移植时代门静脉高压症的治疗选择[J]. 中华消化外科杂志, 2018, 17(10):992-996.
[17]	Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management[J]. Mayo Clin Proc, 2019, 94(4):714-726. doi: S0025-6196(18)31008-5 pmid: 30947834
[18]	Snyder P, Ali R, Poles M, et al. Portal hypertensive gastropathy with a focus on management[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(9):1207-1216. doi: 10.1586/17474124.2015.1059275 URL
[19]	Akatsu T, Yoshida M, Kawachi S, et al. Consequences of living-donor liver transplantation for upper gastrointestinal lesions: high incidence of reflux esophagitis[J]. Dig Dis Sci, 2006, 51(11):2018-2022. doi: 10.1007/s10620-006-9362-3 URL
[20]	Wijdicks EF. Hepatic encephalopathy[J]. N Engl J Med, 2016, 375(17):1660-1670. doi: 10.1056/NEJMra1600561 URL
[21]	Fichet J, Mercier E, Genée O, et al. Prognosis and 1-year mortality of intensive care unit patients with severe he-patic encephalopathy[J]. J Crit Care, 2009, 24(3):364-370. doi: 10.1016/j.jcrc.2009.01.008 URL
[22]	Lucidi C, Ginanni Corradini S, Abraldes JG, et al. He-patic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: evidence by means of 2 independent cohorts[J]. Liver Transpl, 2016, 22(10):1333-1342. doi: 10.1002/lt.24517 URL
[23]	Bernal W, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure? a single centre expe-rience of 3300 patients[J]. J Hepatol, 2013, 59(1):74-80. doi: 10.1016/j.jhep.2013.02.010 URL
[24]	Hopp AE, Dirks M, Petrusch C, et al. Hepatic encephalopathy is reversible in the long term after liver transplantation[J]. Liver Transpl, 2019, 25(11):1661-1672. doi: 10.1002/lt.25626 URL
[25]	Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites[J]. World J Gastroenterol, 2019, 25(28):3738-3752. doi: 10.3748/wjg.v25.i28.3738 URL
[26]	Adebayo D, Neong SF, Wong F. Refractory ascites in li-ver cirrhosis[J]. Am J Gastroenterol, 2019, 114(1):40-47. doi: 10.1038/s41395-018-0185-6 URL
[27]	Arroyo V, Gines P, Gerbes AL, et al. Definition and dia-gnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club[J]. Hepatology, 1996, 23(1):164-176. pmid: 8550036
[28]	Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006, 4(11):1385-1394. doi: 10.1016/j.cgh.2006.08.007 URL
[29]	Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites[J]. N Engl J Med, 2004, 350(16):1646-1654. doi: 10.1056/NEJMra035021 URL
[30]	Moreau R, Delegue P, Pessione F, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites[J]. Liver Int, 2004, 24(5):457-464. doi: 10.1111/j.1478-3231.2004.0991.x URL
[31]	Somsouk M, Kornfield R, Vittinghoff E, et al. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk[J]. Liver Transpl, 2011, 17(2):129-136. doi: 10.1002/lt.22218 URL
[32]	Adebayo D, Neong SF, Wong F. Ascites and hepatorenal syndrome[J]. Clin Liver Dis, 2019, 23(4):659-682. doi: 10.1016/j.cld.2019.06.002 URL

Liver transplantation in treatment of cirrhotic portal hypertension

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 32

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	ZHANG Mengyin, CHEN Ping, YUAN Xiaoqin, CAI Boer, WU Yunlin. Clinical study on endoscopic injection of tissue adhesive with hardener in treatment of gastric varices and follow-up [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 443-447.
[2]	CHEN Xiaojuan, ZHANG Wen, CAI Yu. Transcatheter splenic artery embolization for pancreatic sinistral portal hypertension with gastrointestinal blee-ding: a case report [J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 359-362.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 139-144.
[4]	SUN Longci, ZHANG Bin. Surgical treatment of esophagogastric varices from cavernous transformation of portal vein: one case report [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 226-230.
[5]	CUI Ran, YE Lunhe, WANG Xujing, WANG Yongkun, ZHANG Qiqi, WANG Kaijing, WANG Ming, DAI Chenxin, YANG Ludi, DONG Chunxiu, CHEN Bo. Short-term clinical outcome of laparoscopic splenectomy combined with peripheral cardia disconnection in treatment of portal hypertension in liver cirrhosis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 221-225.
[6]	YANG Tao, YIN Jikai, LU Jianguo. Prospect of laparoscopic surgery in treatment of portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 217-220.
[7]	CHEN Wei, BU Junfeng. Evaluation of liver function in portal hypertension during perioperative stage [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 212-216.
[8]	FAN Xinxin, WU Xingjiang, HE Changsheng. Clinical value of TIPS in treatment of portal hypertension with esophageal and gastric fundus variceal hemorrhage [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 208-211.
[9]	HU Mingli, WANG Qixia, MA Xiong. Drug therapy for esophageal and gastric fundus varices in liver cirrhosis [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 203-207.
[10]	ZENG Ning, FANG Chihua. Use of digital technology and intelligence in diagnosis and treatment for patients with portal hypertension [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 199-202.
[11]	LUO Meng, LI Hongjie, ZHENG Lei. Study on pathogenesis of cirrhotic portal hypertension: current status [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 195-198.
[12]	ZHANG Bin, WU Zhiyong. Individualized treatment of esophagogastric variceal hemorrhage in portal hypertension and selection of surgical procedure [J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 185-188.